BioSpace News Archive

KayoThera, Inc. announces the strengthening of its financial resources through multiple grant awards and expansion of its previously announced Series A financing.

Agile Therapeutics, Inc.'s partnership with Afaxys Pharma is expected to play a key role in propelling the women’s healthcare company toward its $25-$30 million net annual revenue target for 2023.

PrecisionLife, a leading computational biology company driving precision medicine in complex chronic diseases, has announced the results of its long COVID study, providing the first detailed genetic insights into the condition and its commonalities with other diseases, including myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).

SiPhox Health, the leader in building the next generation of lab-grade home health testing with silicon photonics, raised $27 million in funding including a $10M Seed financing and a $17M Series A round.

Roche (SIX: RO, ROG; OTCQX: RHHBY) will showcase a science-driven and patient-centric exhibit at the 2023 American Association of Clinical Chemistry (AACC) Scientific Meeting and Clinical Lab Expo, July 23-27 in Anaheim, California.

Francis Medical, Inc. today announced the first patient has been treated in the company’s VAPOR 2 pivotal clinical study evaluating the safety and efficacy of its Vanquish minimally invasive water vapor ablation therapy for managing prostate cancer.

NANOBIOTIX today announced that the first patient has been injected in a Phase 1/2 study evaluating NBTXR3 activated by radiation therapy in combination with anti-PD-1/L-1 immune checkpoint inhibitors for the treatment of patients with advanced solid tumor malignancies that have spread to lungs (lung metastases) and/or liver (liver metastases).

PTC Therapeutics, Inc. announced that Allan Jacobson, Ph.D., co-founder of PTC and member of the Board of Directors, was presented the 2023 Gruber Genetics Prize for his work in identifying and describing the mechanism of nonsense-mediated mRNA decay today in a ceremony in Australia.

Pfizer Inc. (NYSE: PFE) today announced data from a Phase 2 study investigating its hexavalent capsular polysaccharide (CPS) conjugate Group B Streptococcus (GBS) vaccine candidate, GBS6, being developed for maternal administration to protect infants against invasive GBS disease.

Vial announced the enrollment of the first patient in the pivotal clinical trial, “COOL-3s”, evaluating the OcuCool system, developed by RecensMedical, Inc. (“RecensMedical”), a distinguished medical device company based in South Korea.